Concepedia

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lars Lindholm, Hans Ibsen, Björn Dahlöf, Richard B. Devereux, Gareth Beevers, Ulf dé Fairé, Frej Fyhrquist, Stevo Julius, Sverre E. Kjeldsen, Krister Kristiansson,

The Lancet · 2002 · 1.6K citations · 29 references

DOI

Concepts

References

29

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

New England Journal of Medicine · 2000 · 8.6K citations · Full text

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw et al. · New England Journal of Medicine · 2001 · 7.4K citations · Full text

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke et al. · New England Journal of Medicine · 2001 · 5.9K citations · Full text

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

Lennart Hansson, Alberto Zanchetti, S. George Carruthers et al. · The Lancet · 1998 · 5.8K citations

, , +12

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen et al. · The Lancet · 2002 · 5.4K citations

, , +7